The thesis

STRW owns and leases healthcare properties, with 7.1% revenue growth and 22.6x P/E. The conviction score is 40/100, indicating moderate confidence. Analysts rate it a buy, despite a gross margin of 5310.0% and net margin of 525.0%. This discrepancy makes the setup interesting,

Why now

The current macro context, with China's chip tool push and US-China tensions, may impact STRW's valuation. The company's revenue growth and high margins make it a compelling watchlist candidate, especially with a conviction score of 40/100,

What to watch

The company's future revenue growth and margin performance will be key indicators to watch over the next quarter. Investors should also monitor changes in analyst consensus and conviction scores, as well as any updates on the US-China trade tensions and their potential impact on STRW's valuation

Key risks

Valuation risk is a major concern, given the high P/E ratio of 22.6x. Execution risk is also present, as the company's high margins may not be sustainable. Macro risk, such as changes in healthcare policy, could also impact STRW's business,